Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation
Xiao-xiao
Guo
ab,
Zhen-hu
Guo
c,
Jing-song
Lu
c,
Wen-sheng
Xie
c,
Qiu-zi
Zhong
d,
Xiao-dan
Sun
c,
Xiu-mei
Wang
c,
Jian-ye
Wang
*ab,
Ming
Liu
*a and
Ling-yun
Zhao
*c
aDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China
bGraduate School of Peking Union Medical College, Beijing, 100730, China
cKey Laboratory of Advanced Materials, Ministry of Education of China, School of Materials Science and Engineering, Tsinghua University, Beijing, 100084, China
dDepartment of Radiotherapy, National Center of Gerontology, Institute of Geriatric Medicine, Beijing Hospital, Chinese Academy of Medical Science, Beijing, 100730, China
First published on 25th April 2022
Abstract
Correction for ‘All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation’ by Xiao-xiao Guo et al., Nanoscale, 2021, 13, 14525–14537, https://doi.org/10.1039/D1NR03869A.
The authors regret that there was an error in the affiliation labels for Jian-ye Wang in the original manuscript. The correct affiliations are as shown herein.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2022 |